Skip to main content
Supplement Research and Comparison WebsiteBest Price Guarantee
Supplement Research and Comparison Website

Bifidobacterium animalis subsp. lactis Bi‐07 contributes to increasing lactose digestion: evaluation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006

  • 2020-07
  • EFSA Journal 18(7)
    • D. Turck
    • J. Castenmiller
    • S. de Henauw
    • K. Hirsch‐Ernst
    • J. Kearney
    • H. Knutsen
    • A. Maciuk
    • I. Mangelsdorf
    • H. Mcardle
    • A. Naska
    • C. Peláez
    • K. Pentieva
    • F. Thies
    • S. Tsabouri
    • M. Vinceti
    • Jean‐Loui s Bresson
    • A. Siani

Abstract

Following an application from DuPont Nutrition Biosciences ApS submitted for authorisation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006 via the Competent Authority of Ireland, the EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) was asked to deliver an opinion on the scientific substantiation of a health claim related to Bifidobacterium animalis subsp. lactis Bi-07 (Bi-07) and contribution to increasing lactose digestion. The scope of the application was proposed to fall under a health claim based on newly developed scientific evidence. The food proposed by the applicant as the subject of the health claim is Bi-07. The Panel considers that Bi-07 is sufficiently characterised. The claimed effect proposed by the applicant is 'improvement of lactose digestion'. The Panel considers that increasing lactose digestion is a beneficial physiological effect for individuals with lactose maldigestion provided that the symptoms of lactose maldigestion are improved. Two human intervention studies which investigated a single dose effect of Bi-07 on lactose digestion using the hydrogen breath test, as well as on gastrointestinal symptoms were submitted. These studies show that consumption of Bi-07 (1012 CFU) increases lactose digestion in individuals with lactose maldigestion and that Bi-07 exhibits lactase activity in vitro. However, these studies provide no evidence that increasing lactose digestion through the consumption of Bi-07 (1012 CFU) improves gastrointestinal symptoms of lactose maldigestion, which is considered a beneficial physiological effect. The Panel concludes that a cause and effect relationship has not been established between the consumption of Bifidobacterium animalis subsp. lactis Bi-07 and a beneficial physiological effect (i.e. the improvement of symptoms of lactose maldigestion) in individuals with lactose maldigestion.

Keywords: Bifidobacterium animalis subsp. lactis Bi‐07; health claim; lactase; lactose maldigestion.

Research Insights

SupplementHealth OutcomeEffect TypeEffect Size
Bifidobacterium lactis Bi-07Improved Lactose DigestionNeutral
Moderate
Back to top